999 related articles for article (PubMed ID: 32114075)
21. [Comparison of pathological changes and pathogenic mechanisms caused by H1N1 influenza virus, highly pathogenic H5N1 avian influenza virus, SARS-CoV, MERS-CoV and 2019-nCoV].
Liu M; Feng RE; Li Q; Zhang HK; Wang YG
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):511-516. PubMed ID: 32392945
[TBL] [Abstract][Full Text] [Related]
22. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
23. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
24. Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS.
Liang K
Infect Genet Evol; 2020 Aug; 82():104306. PubMed ID: 32278147
[TBL] [Abstract][Full Text] [Related]
25. The novel zoonotic COVID-19 pandemic: An expected global health concern.
Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of depression during the SARS, MERS, and COVID-19 pandemics: A protocol for overview of systematic reviews.
Du L; Chen YM; Li Y; Yuan W; Wang JS
Medicine (Baltimore); 2020 Sep; 99(38):e22235. PubMed ID: 32957366
[TBL] [Abstract][Full Text] [Related]
27. Preparing for emerging respiratory pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2.
Al-Tawfiq JA; Garout MA; Gautret P
Infez Med; 2020 Jun; 28(suppl 1):64-70. PubMed ID: 32532941
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of SARS-CoV-2 infection based on CT scan vs RT-PCR: reflecting on experience from MERS-CoV.
Al-Tawfiq JA; Memish ZA
J Hosp Infect; 2020 Jun; 105(2):154-155. PubMed ID: 32147407
[No Abstract] [Full Text] [Related]
29. Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2.
Franquet T; Jeong YJ; Lam HYS; Wong HYF; Chang YC; Chung MJ; Lee KS
Br J Radiol; 2020 Aug; 93(1112):20200515. PubMed ID: 32584604
[TBL] [Abstract][Full Text] [Related]
30. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
31. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
32. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
Asrani P; Hasan GM; Sohal SS; Hassan MI
OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
[TBL] [Abstract][Full Text] [Related]
33. A comparative overview of COVID-19, MERS and SARS: Review article.
Liu J; Xie W; Wang Y; Xiong Y; Chen S; Han J; Wu Q
Int J Surg; 2020 Sep; 81():1-8. PubMed ID: 32730205
[TBL] [Abstract][Full Text] [Related]
34. Pediatric SARS, H1N1, MERS, EVALI, and Now Coronavirus Disease (COVID-19) Pneumonia: What Radiologists Need to Know.
Foust AM; Winant AJ; Chu WC; Das KM; Phillips GS; Lee EY
AJR Am J Roentgenol; 2020 Sep; 215(3):736-744. PubMed ID: 32352308
[No Abstract] [Full Text] [Related]
35. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.
Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS
Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933
[TBL] [Abstract][Full Text] [Related]
36. Emergence of SARS-like coronavirus in China: An update.
Zhang Z; Xiao K; Zhang X; Roy A; Shen Y
J Infect; 2020 May; 80(5):e28-e29. PubMed ID: 32173381
[No Abstract] [Full Text] [Related]
37. Emergence of SARS-like coronavirus poses new challenge in China.
Wang R; Zhang X; Irwin DM; Shen Y
J Infect; 2020 Mar; 80(3):350-371. PubMed ID: 32007524
[No Abstract] [Full Text] [Related]
38. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
39. Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19).
Al-Tawfiq JA; Rodriguez-Morales AJ
J Hosp Infect; 2020 Jun; 105(2):111-112. PubMed ID: 32277963
[No Abstract] [Full Text] [Related]
40. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
